KR100249937B1 - 인간 인터루킨-6 수용체에 대한 재구성 인간 항체 - Google Patents

인간 인터루킨-6 수용체에 대한 재구성 인간 항체 Download PDF

Info

Publication number
KR100249937B1
KR100249937B1 KR1019930703229A KR930703229A KR100249937B1 KR 100249937 B1 KR100249937 B1 KR 100249937B1 KR 1019930703229 A KR1019930703229 A KR 1019930703229A KR 930703229 A KR930703229 A KR 930703229A KR 100249937 B1 KR100249937 B1 KR 100249937B1
Authority
KR
South Korea
Prior art keywords
chain
region
human
antibody
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1019930703229A
Other languages
English (en)
Korean (ko)
Inventor
마사유키 즈지야
고 사토
마리 마가레트 벤딕
스티븐 타란 존스
죠세 윌리암 샐다나
Original Assignee
나가야마 오사무
쥬가이 세이야쿠 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26370596&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100249937(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from JP3095476A external-priority patent/JPH05236966A/ja
Priority claimed from JP4032084A external-priority patent/JPH05227970A/ja
Application filed by 나가야마 오사무, 쥬가이 세이야쿠 가부시키가이샤 filed Critical 나가야마 오사무
Application granted granted Critical
Publication of KR100249937B1 publication Critical patent/KR100249937B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1019930703229A 1991-04-25 1992-04-24 인간 인터루킨-6 수용체에 대한 재구성 인간 항체 Expired - Lifetime KR100249937B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP95476/1991 1991-04-25
JP3095476A JPH05236966A (ja) 1991-04-25 1991-04-25 ヒトインターロイキン−６レセプターに対するマウスモノクローナル抗体の可変領域をコードするｄｎａ
JP32084/1992 1992-02-19
JP4032084A JPH05227970A (ja) 1992-02-19 1992-02-19 ヒトインターロイキン−６受容体に対する再構成ヒト抗体
PCT/JP1992/000544 WO1992019759A1 (fr) 1991-04-25 1992-04-24 Anticorps humains reconstitues diriges contre un recepteur de l'interleukine 6 humaine

Publications (1)

Publication Number Publication Date
KR100249937B1 true KR100249937B1 (ko) 2000-04-01

Family

ID=26370596

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930703229A Expired - Lifetime KR100249937B1 (ko) 1991-04-25 1992-04-24 인간 인터루킨-6 수용체에 대한 재구성 인간 항체

Country Status (16)

Country Link
US (3) US5795965A (enExample)
EP (1) EP0628639B1 (enExample)
JP (6) JP3370324B2 (enExample)
KR (1) KR100249937B1 (enExample)
AT (1) ATE181575T1 (enExample)
AU (2) AU668349B2 (enExample)
DE (2) DE69229482T2 (enExample)
DK (1) DK0628639T3 (enExample)
ES (1) ES2134212T3 (enExample)
GR (1) GR3031174T3 (enExample)
HU (1) HU218140B (enExample)
LU (1) LU91556I2 (enExample)
NL (1) NL300383I2 (enExample)
RU (1) RU2139351C1 (enExample)
TW (1) TW205553B (enExample)
WO (1) WO1992019759A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101510831B1 (ko) * 2012-05-11 2015-04-10 가톨릭대학교 산학협력단 항 ｉｌ-６ｒ 및 ｔｎｆｒ２을 포함하는 이중특이적 단백질을 발현하는 미니서클 벡터를 포함하는 줄기세포 치료제
KR101510302B1 (ko) * 2012-05-11 2015-04-10 가톨릭대학교 산학협력단 Ｉｌ-６ 수용체를 표적으로 하는 항체가 생성되도록 미니서클 벡터를 통해 형질전환된 줄기세포 치료제
KR101510830B1 (ko) 2012-05-11 2015-04-10 가톨릭대학교 산학협력단 생리활성 단백질을 발현하는 미니서클을 이용하여 형질전환된 줄기세포를 통한 치료법

Families Citing this family (336)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995006119A1 (en) * 1993-08-24 1995-03-02 Scotgen Limited Recombinant humanized anti-human immunodeficiency virus antibody
US5472693A (en) * 1993-02-16 1995-12-05 The Dow Chemical Company Family of anti-carcinoembryonic antigen chimeric antibodies
AU6808194A (en) * 1993-05-31 1994-12-20 Chugai Seiyaku Kabushiki Kaisha Reconstructed human antibody against human interleukin-6
US5914110A (en) * 1993-09-07 1999-06-22 Smithkline Beecham Corporation Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
EP0729976A1 (en) * 1993-11-19 1996-09-04 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human medulloblastomatous cell
WO1995029690A1 (en) * 1994-04-29 1995-11-09 The Trustees Of The University Of Pennsylvania Biologically active peptides and methods of identifying the same
US8017121B2 (en) 1994-06-30 2011-09-13 Chugai Seiyaku Kabushika Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
EP0783893B1 (en) 1994-10-07 2012-04-04 Chugai Seiyaku Kabushiki Kaisha Inhibition of abnormal growth of synovial cells using il-6 antagonist as active ingredient
WO1996012503A1 (en) * 1994-10-21 1996-05-02 Chugai Seiyaku Kabushiki Kaisha Remedy for diseases caused by il-6 production
CA2211578C (en) * 1995-02-13 2010-09-21 Chugai Seiyaku Kabushiki Kaisha Muscle protein proteolysis inhibiting agent containing il-6 receptor antibody
DE69735888T2 (de) * 1996-06-27 2006-11-02 Chugai Seiyaku K.K. Mittel gegen myelome, welches zusammen mit antitumorwirkstoffen auf der basis von stickstoffsenfgasen verwendet werden kann
SK40599A3 (en) 1996-09-26 2000-06-12 Chugai Pharmaceutical Co Ltd Antibody against human parathormone related peptides
UA76934C2 (en) * 1996-10-04 2006-10-16 Chugai Pharmaceutical Co Ltd Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
KR100655979B1 (ko) 1997-02-12 2006-12-08 츄가이 세이야꾸 가부시키가이샤 임파구계 종양의 치료제
AU736282B2 (en) 1997-03-21 2001-07-26 Chugai Seiyaku Kabushiki Kaisha A preventive or therapeutic agent for sensitized T cell- mediated diseases comprising IL-6 antagonist as an active ingredient
TR199902800T2 (xx) 1997-05-15 2000-04-21 Chugai Seiyaku Kabushiki Kaisha Ka�eksiyi tedavi edici madde.
US20020187150A1 (en) * 1997-08-15 2002-12-12 Chugai Seiyaku Kabushiki Kaisha Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
PT1004315E (pt) 1997-08-15 2008-07-09 Chugai Pharmaceutical Co Ltd Profilácticos e/ou medicamentos contendo anticorpos neutralizantes anti-receptor de il-6 para reduzir a excreção de proteínas urinárias no lúpus eritematoso sistémico
HU225539B1 (en) 1998-03-17 2007-02-28 Chugai Pharmaceutical Co Ltd Preventives or remedies for inflammatory intestinal diseases containing as the active ingredient antibody against il-6 receptor
AU752730B2 (en) 1998-04-03 2002-09-26 Chugai Seiyaku Kabushiki Kaisha Humanized antibody against human tissue factor (TF) and process for constructing humanized antibody
WO2000010607A1 (en) * 1998-08-24 2000-03-02 Chugai Seiyaku Kabushiki Kaisha Preventives or remedies for pancreatitis containing il-6 antagonists as the active ingredient
DE69942782D1 (de) 1998-11-27 2010-10-28 Ucb Sa Zusammensetzungen und Verfahren zur Erhöhung der Knochenmineralisierung
US7696325B2 (en) 1999-03-10 2010-04-13 Chugai Seiyaku Kabushiki Kaisha Polypeptide inducing apoptosis
AU7078200A (en) * 1999-08-27 2001-03-26 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Polypeptides, comprising il-6 ligand-binding receptor domains and related nucleic acids, antibodies, compositions, and methods of use
HUP0203486A2 (hu) 1999-10-01 2003-02-28 Chugai Seiyaku Kabushiki Kaisha Véralvadással összefüggő betegségek megelőzése és kezelése
GB0002666D0 (en) 2000-02-04 2000-03-29 Univ London Blockade of voltage dependent sodium channels
AU2001252618A1 (en) 2000-04-28 2001-11-12 Chugai Seiyaku Kabushiki Kaisha Cell proliferation inhibitors
US8632778B2 (en) 2000-08-11 2014-01-21 Chugai Seiyaku Kabushiki Kaisha Stabilized anti-interleukin-6 antibody-containing preparations
WO2002032374A2 (en) * 2000-10-18 2002-04-25 Immunex Corporation Methods for treating il-18 mediated disorders
US8034903B2 (en) 2000-10-20 2011-10-11 Chugai Seiyaku Kabushiki Kaisha Degraded TPO agonist antibody
EP1327681A4 (en) 2000-10-20 2004-09-01 Chugai Pharmaceutical Co Ltd Degraded agonist antibodies
US20040242847A1 (en) 2000-10-20 2004-12-02 Naoshi Fukushima Degraded agonist antibody
AU2002210952B2 (en) 2000-10-25 2007-01-11 Chugai Seiyaku Kabushiki Kaisha Preventives or remedies for psoriasis containing as the active ingredient IL-6 antagonist
JP4889187B2 (ja) * 2000-10-27 2012-03-07 中外製薬株式会社 Ｉｌ−６アンタゴニストを有効成分として含有する血中ｍｍｐ−３濃度低下剤
AU2000279624A1 (en) * 2000-10-27 2002-05-15 Chugai Seiyaku Kabushiki Kaisha Blooe vegf level-lowering agent containing il-6 antagonist as the active ingredient
EP1364657B1 (en) 2001-02-07 2016-12-28 Chugai Seiyaku Kabushiki Kaisha Remedies for myelocytic leukemia
AU2002322478A1 (en) * 2001-03-02 2002-12-16 Medimmune, Inc. Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
EP3088412B1 (en) 2001-03-09 2021-05-05 Chugai Seiyaku Kabushiki Kaisha Protein purification method
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
JP4236934B2 (ja) 2001-04-17 2009-03-11 中外製薬株式会社 界面活性剤の定量方法
US20100056762A1 (en) * 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
DE60234094D1 (de) * 2001-05-11 2009-12-03 Ludwig Inst For Cancer Res Ltd Spezifische bindungsproteine und ihre verwendung
WO2003068260A1 (fr) * 2002-02-14 2003-08-21 Chugai Seiyaku Kabushiki Kaisha Produits pharmaceutiques en solution contenant des anticorps
GB0208041D0 (en) * 2002-04-08 2002-05-22 Lonza Biologics Plc Method of culturing animal cells
WO2004022597A1 (ja) 2002-09-04 2004-03-18 Chugai Seiyaku Kabushiki Kaisha Gpc3の血中可溶化ｎ端ﾍﾟﾌﾟﾁﾄﾞに対する抗体
EP1498137A1 (en) * 2002-04-25 2005-01-19 Chugai Seiyaku Kabushiki Kaisha Remedy for lung cancer
JP4753578B2 (ja) * 2002-06-03 2011-08-24 ジェネンテック， インコーポレイテッド 合成抗体ファージライブラリー
AU2003257536A1 (en) 2002-08-27 2004-03-19 Chugai Seiyaku Kabushiki Kaisha Method of stabilizing protein solution preparation
EP2261230B1 (en) 2002-09-11 2017-05-10 Chugai Seiyaku Kabushiki Kaisha Protein purification method
MXPA05008713A (es) * 2003-02-24 2005-09-20 Chugai Pharmaceutical Co Ltd Agente terapeutico para dano de medula espinal que comprende antagonista de interluceina-6.
JP2004279086A (ja) 2003-03-13 2004-10-07 Konica Minolta Holdings Inc 放射線画像変換パネル及び放射線画像変換パネルの製造方法
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
EP1636270B1 (en) 2003-06-16 2016-07-20 UCB Pharma S.A. Antibodies specific for sclerostin and methods for increasing bone mineralization
TW200510532A (en) 2003-07-15 2005-03-16 Chugai Pharmaceutical Co Ltd IgM production by transformed cell and method of quantifying the same
US20070134242A1 (en) 2003-10-17 2007-06-14 Chugai Seiyaku Kabushiki Kaisha Mesothelioma therapeutic agent
EP2270152A1 (en) * 2003-12-03 2011-01-05 Chugai Seiyaku Kabushiki Kaisha Expression system using mammalian beta-actin promoter
AR048210A1 (es) 2003-12-19 2006-04-12 Chugai Pharmaceutical Co Ltd Un agente preventivo para la vasculitis.
US8617550B2 (en) 2003-12-19 2013-12-31 Chugai Seiyaku Kabushiki Kaisha Treatment of vasculitis with IL-6 antagonist
WO2005080429A2 (en) * 2004-02-11 2005-09-01 Warner-Lambert Company Llc Methods of treating osteoarthritis with anti-il-6 or anti-il6 receptor antibodies
WO2005079479A2 (en) * 2004-02-17 2005-09-01 Absalus, Inc. Super-humanized antibodies against respiratory syncytial virus
US7767792B2 (en) * 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides
JPWO2005090405A1 (ja) 2004-03-24 2008-04-17 中外製薬株式会社 インターロイキン−６受容体に対するヒト型化抗体のサブタイプ
AR048335A1 (es) 2004-03-24 2006-04-19 Chugai Pharmaceutical Co Ltd Agentes terapeuticos para trastornos del oido interno que contienen un antagonista de il- 6 como un ingrediente activo
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
GB0410627D0 (en) * 2004-05-12 2004-06-16 Scancell Ltd Specific binding members
WO2006046661A1 (ja) * 2004-10-28 2006-05-04 Osaka University インターロイキン－６阻害剤
DK1835022T3 (en) 2005-01-05 2015-02-23 Chugai Pharmaceutical Co Ltd CELL CULTIVATION PROCEDURE AND UTILIZATION OF THIS
US20090047278A1 (en) * 2005-02-28 2009-02-19 Eisai R & D Management Co., Ltd. Novel Combinational Use of Sulfonamide Compound
EP1870458B1 (en) 2005-03-31 2018-05-09 Chugai Seiyaku Kabushiki Kaisha sc(Fv)2 STRUCTURAL ISOMERS
TWI671403B (zh) * 2005-03-31 2019-09-11 中外製藥股份有限公司 控制組裝之多肽的製造方法
PA8672101A1 (es) 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
CN101262885B (zh) 2005-06-10 2015-04-01 中外制药株式会社 含有sc(Fv)2的药物组合物
CA2610987C (en) 2005-06-10 2013-09-10 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
CA2618796C (en) * 2005-08-11 2018-01-02 Arpi Matossian-Rogers Peptides for treatment and diagnosis of autoimmune disease
RU2446826C2 (ru) 2005-10-14 2012-04-10 Фукуока Юниверсити Агенты для подавления повреждения трансплантированных островков после трансплантации островков
JP5191235B2 (ja) 2005-10-21 2013-05-08 中外製薬株式会社 心疾患治療剤
EP1957531B1 (en) 2005-11-07 2016-04-13 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
EP1964574B1 (en) 2005-11-14 2016-09-07 Cellmid Limited Method for treatment or prevention of disease associated with functional disorder of regulatory t cell
AR057582A1 (es) * 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
AR057941A1 (es) 2005-11-25 2007-12-26 Univ Keio Agentes terapeuticos para el cancer de prostata
EP1977763A4 (en) 2005-12-28 2010-06-02 Chugai Pharmaceutical Co Ltd ANTIBODY-CONTAINING STABILIZING PREPARATION
AR059213A1 (es) 2006-01-27 2008-03-19 Univ Keio Agentes terapeuticos para enfermedades que involucran neovascularizacion coroidal
WO2007108505A1 (ja) 2006-03-22 2007-09-27 Chugai Seiyaku Kabushiki Kaisha エリスロポエチン溶液製剤
IN2014DN10515A (enExample) 2006-03-31 2015-08-21 Chugai Pharmaceutical Co Ltd
WO2007114325A1 (ja) 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha 二重特異性抗体を精製するための抗体改変方法
CA2648644C (en) 2006-04-07 2016-01-05 Osaka University Muscle regeneration promoter
US8741643B2 (en) 2006-04-28 2014-06-03 Lifescan, Inc. Differentiation of pluripotent stem cells to definitive endoderm lineage
EP2027157B1 (en) * 2006-05-25 2014-08-06 Glaxo Group Limited Modified humanised anti-interleukin-18 antibodies
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
RS52176B (sr) * 2006-06-02 2012-08-31 Regeneron Pharmaceuticals Inc. Antitela visokog afiniteta prema humanom il-6 receptoru
PL2032166T3 (pl) 2006-06-13 2013-09-30 Oncomed Pharm Inc Kompozycje i sposoby diagnozowania i leczenia nowotworów
CN101573383B (zh) 2006-06-21 2015-05-13 肿瘤疗法科学股份有限公司 靶向肿瘤的针对卷曲同源物10的单克隆抗体及其用途
AU2007285695B2 (en) 2006-08-18 2012-05-24 Ablynx N.V. Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling
US20080081041A1 (en) * 2006-09-29 2008-04-03 Jeffrey Nemeth Method of Using IL6 Antagonists with Mitoxantrone for Prostate Cancer
KR101508019B1 (ko) 2007-01-23 2015-04-06 고쿠리츠 다이가쿠 호우징 신슈 다이가쿠 만성 거부반응 억제제
US8088617B2 (en) 2007-01-24 2012-01-03 Oncomed Pharmaceuticals, Inc. Antibodies that bind the glutamate ligand binding region of Notch1
CA2676244C (en) 2007-01-25 2017-01-17 Kwok-Kin Wong Use of anti-egfr antibodies in treatment of egfr mutant mediated disease
CL2008000719A1 (es) 2007-03-12 2008-09-05 Univ Tokushima Chugai Seiyaku Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
US8252286B2 (en) * 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US7906117B2 (en) * 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
KR101741731B1 (ko) 2007-05-21 2017-05-30 앨더바이오 홀딩스 엘엘씨 Ｉｌ-６에 대한 항체 및 이의 용도
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
KR20170036814A (ko) * 2007-05-21 2017-04-03 앨더바이오 홀딩스 엘엘씨 신규한 래빗 항체 인간화 방법 및 인간화된 래빗 항체
US20090238825A1 (en) * 2007-05-21 2009-09-24 Kovacevich Brian R Novel rabbit antibody humanization methods and humanized rabbit antibodies
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US8178101B2 (en) * 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
JP5142265B2 (ja) * 2007-05-28 2013-02-13 独立行政法人産業技術総合研究所 抗モータリン抗体のパラトープ及びエピトープ
US9080145B2 (en) 2007-07-01 2015-07-14 Lifescan Corporation Single pluripotent stem cell culture
WO2009014263A1 (ja) 2007-07-26 2009-01-29 Osaka University インターロイキン６受容体阻害剤を有効成分とする眼炎症疾患治療剤
KR101617243B1 (ko) 2007-07-31 2016-05-02 라이프스캔, 인코포레이티드 인간 배아 줄기 세포의 분화
CA2696360C (en) 2007-08-14 2018-11-20 Ludwig Institute For Cancer Research Monoclonal antibody targeting the egfr receptor and uses thereof
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
MX336725B (es) 2007-09-26 2016-01-28 Chugai Pharmaceutical Co Ltd Metodo de modificacion del punto isoelectrico de anticuerpos medinate la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
WO2009041621A1 (ja) 2007-09-26 2009-04-02 Chugai Seiyaku Kabushiki Kaisha 抗il-6レセプター抗体
DK3059246T3 (en) * 2007-09-26 2018-10-01 Chugai Pharmaceutical Co Ltd Modified constant region of an antibody
JP5264752B2 (ja) 2007-10-02 2013-08-14 中外製薬株式会社 インターロイキン６受容体阻害剤を有効成分とする移植片対宿主病治療剤
BRPI0818674B1 (pt) 2007-10-15 2023-01-17 Chugai Seiyaku Kabushiki Kaisha Métodos para produção de um anticorpo inteiro ou de um fragmento do mesmo e para preparação de fármacos, bem como vetor recombinante
CA3123528C (en) 2007-11-27 2026-01-13 Lifescan, Inc. Differentiation of human embryonic stem cells to pancreatic cells
BRPI0821110B8 (pt) 2007-12-05 2021-05-25 Chugai Pharmaceutical Co Ltd anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo
EP2241333A1 (en) 2007-12-12 2010-10-20 National Cancer Center Therapeutic agent for mll leukemia and moz leukemia of which molecular target is m-csf receptor, and use thereof
PE20091174A1 (es) * 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
WO2009095489A2 (en) * 2008-02-01 2009-08-06 Ablynx N.V. Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
BR122017025207B1 (pt) 2008-02-21 2021-03-16 Centocor Ortho Biotech Inc superfície que faz parte de um recipiente ou matriz destinada para uso em uma cultura de células ou análises, desprovida de uma camada de células alimentadoras e desprovida de uma camada adsorvente
TWI700293B (zh) 2008-04-11 2020-08-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗體
US8623648B2 (en) 2008-04-24 2014-01-07 Janssen Biotech, Inc. Treatment of pluripotent cells
JP5646457B2 (ja) * 2008-04-29 2014-12-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
AU2009246430B2 (en) 2008-05-13 2015-07-02 Novimmune S.A. Anti-IL-6/IL-6R antibodies and methods of use thereof
JP2011523853A (ja) 2008-06-03 2011-08-25 アボット・ラボラトリーズ 二重可変ドメイン免疫グロブリン及びその使用
AR072000A1 (es) 2008-06-03 2010-07-28 Abbott Lab Proteinas de union multivalentes con capacidad de unir dos o mas antigenos y usos de la misma
US10717781B2 (en) * 2008-06-05 2020-07-21 National Cancer Center Neuroinvasion inhibitor
US8188235B2 (en) 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
US20100015711A1 (en) 2008-06-30 2010-01-21 Janet Davis Differentiation of Pluripotent Stem Cells
BRPI0915448A2 (pt) 2008-07-08 2015-11-10 Abbott Lab imunoglobulinas de domínio variável duplo para prostaglandina e2 e usos das mesmas
EP2307051B1 (en) 2008-07-08 2015-02-11 OncoMed Pharmaceuticals, Inc. Notch-binding agents and antagonists and methods of use thereof
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
BRPI0919885A2 (pt) 2008-10-31 2015-08-11 Centocor Ortho Biotech Inc Diferenciação de células-tronco embrionárias humanas para a linhagem endócrina pancreática
US20100124781A1 (en) 2008-11-20 2010-05-20 Shelley Nelson Pluripotent Stem Cell Culture on Micro-Carriers
AU2009316583B2 (en) 2008-11-20 2016-04-21 Janssen Biotech, Inc. Methods and compositions for cell attachment and cultivation on planar substrates
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US9452227B2 (en) * 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
EP2409991B1 (en) 2009-03-19 2017-05-03 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
JP5787446B2 (ja) 2009-03-19 2015-09-30 中外製薬株式会社 抗体定常領域改変体
WO2010115995A2 (en) 2009-04-10 2010-10-14 Ablynx Nv Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
AU2010233658B2 (en) 2009-04-10 2013-11-28 Ablynx Nv Improved amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of IL-6R related diseases and disorders
AU2010242840B2 (en) * 2009-05-01 2014-04-17 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
CN102459344A (zh) 2009-05-15 2012-05-16 中外制药株式会社 抗axl抗体
BR112012001480A2 (pt) 2009-07-20 2015-09-01 Janssen Biotech Inc Diferenciação de células-tronco embriônicas humanas
TWI523661B (zh) * 2009-07-31 2016-03-01 前田慎 Anti-IL-6 receptor antibody in the manufacture of inhibitors of metastatic inhibition of lung cancer metastasis to the liver
TW201118166A (en) 2009-09-24 2011-06-01 Chugai Pharmaceutical Co Ltd HLA class I-recognizing antibodies
US10150808B2 (en) 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
TW201119676A (en) * 2009-10-15 2011-06-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
EP4406615A3 (en) 2009-10-26 2024-12-11 F. Hoffmann-La Roche AG Method for the production of a glycosylated immunoglobulin
UY32979A (es) * 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
CN102740888B (zh) 2009-11-24 2016-10-12 奥尔德生物制药公司 Il-6抗体及其用途
JP5728718B2 (ja) 2009-12-28 2015-06-03 オンコセラピー・サイエンス株式会社 抗ｃｄｈ３抗体およびその使用
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
WO2011088215A2 (en) * 2010-01-13 2011-07-21 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
TWI505838B (zh) 2010-01-20 2015-11-01 中外製藥股份有限公司 Stabilized antibody solution containing
WO2011109279A2 (en) 2010-03-01 2011-09-09 Centocor Ortho Biotech Inc. Methods for purifying cells derived from pluripotent stem cells
WO2011108638A1 (ja) 2010-03-04 2011-09-09 大日本住友製薬株式会社 炎症性腸疾患用薬剤
EP2543730B1 (en) 2010-03-04 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
EP3372617B1 (en) 2010-04-02 2024-07-24 Amunix Pharmaceuticals, Inc. Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
WO2011128096A1 (en) 2010-04-16 2011-10-20 Roche Diagnostics Gmbh Polymorphism markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment
US9752125B2 (en) 2010-05-12 2017-09-05 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
SMT202000095T1 (it) 2010-05-14 2020-03-13 Amgen Inc Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
JP5904552B2 (ja) 2010-05-28 2016-04-13 国立研究開発法人国立がん研究センター 膵癌治療剤
EP4115906A1 (en) 2010-05-28 2023-01-11 Chugai Seiyaku Kabushiki Kaisha Antitumor t cell response enhancer
US8858944B2 (en) 2010-06-02 2014-10-14 Sumitomo Dainippon Pharma Co., Ltd. Treatment drug for autoimmune diseases and allergic diseases
EP2576824A2 (en) 2010-06-07 2013-04-10 Roche Diagnostics GmbH Gene expression markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment
AR081434A1 (es) * 2010-06-10 2012-08-29 Lilly Co Eli Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo
EP3252072A3 (en) 2010-08-03 2018-03-14 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
SG187938A1 (en) 2010-08-26 2013-04-30 Abbvie Inc Dual variable domain immunoglobulins and uses thereof
CA2809300A1 (en) 2010-08-31 2012-03-08 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
DK4108671T3 (da) 2010-10-01 2025-01-06 Modernatx Inc Modificerede nukleosider, nukleotider og nukleinsyrer samt anvendelser deraf
US8790649B2 (en) * 2010-10-29 2014-07-29 Immunogen, Inc. EGFR-binding molecules and immunoconjugates thereof
AU2011320318B9 (en) 2010-10-29 2015-11-19 Immunogen, Inc. Non-antagonistic EGFR-binding molecules and immunoconjugates thereof
EP2638067A2 (en) 2010-11-08 2013-09-18 Genentech, Inc. Subcutaneously administered anti-il-6 receptor antibody
JP6013915B2 (ja) 2010-11-17 2016-10-25 中外製薬株式会社 血液凝固第ｖｉｉｉ因子の機能を代替する機能を有する多重特異性抗原結合分子
US8992908B2 (en) 2010-11-23 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of oral mucositis
KR102568454B1 (ko) 2010-11-30 2023-08-18 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복해서 결합하는 항원 결합 분자
BR112013018740A2 (pt) 2011-01-28 2019-01-08 Sanofi Sa anticorpos humanos para pcsk9 para uso em métodos de tratamento de grupos específicos de indivíduos
EP3604330A1 (en) 2011-02-25 2020-02-05 Chugai Seiyaku Kabushiki Kaisha Fcgammariib-specific fc antibody
US9133272B2 (en) 2011-03-01 2015-09-15 Amgen Inc. Bispecific binding agents
JP2014511842A (ja) 2011-03-25 2014-05-19 アムジエン・インコーポレーテツド 抗スクレロスチン抗体結晶およびその製剤
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
DK3006464T3 (en) 2011-06-10 2018-09-17 Canada Minister Nat Defence ANTIRICIN ANTIBODIES AND APPLICATIONS THEREOF
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
IL312872A (en) 2011-06-28 2024-07-01 Inhibrx Inc Methods for purifying fusion proteins containing serphin
WO2013012022A1 (ja) 2011-07-19 2013-01-24 中外製薬株式会社 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
WO2013017656A1 (en) 2011-08-02 2013-02-07 Medizinische Universität Wien Antagonists of ribonucleases for treating obesity
DK2739311T3 (en) 2011-08-04 2018-04-23 Amgen Inc Method of treating bone slit defects
WO2013017691A1 (en) 2011-08-04 2013-02-07 Medizinische Universität Innsbruck Cahgt1p inhibitors for use in the treatment of candidiasis
CA2847302C (en) 2011-09-01 2021-02-16 Chugai Seiyaku Kabushiki Kaisha Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US10138302B2 (en) 2011-09-23 2018-11-27 Ablynx N.V. Methods for treating rheumatoid arthritis by administering interleukin-6 receptor antibodies
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
TW201817745A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
DE102011083811A1 (de) * 2011-09-30 2013-04-04 Airbus Operations Gmbh Sitzvorrichtung für ein Luft- oder Raumfahrzeug
JP6113737B2 (ja) 2011-10-03 2017-04-12 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
WO2013059548A1 (en) 2011-10-19 2013-04-25 Sanofi Compositions and methods for treating cancer using jak2 inhibitor
EP3559049B1 (en) 2011-10-28 2025-06-11 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
JO3370B1 (ar) 2011-11-10 2019-03-13 Regeneron Pharma طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
KR20140105765A (ko) 2011-11-21 2014-09-02 이뮤노젠 아이엔씨 EGfr 항체 세포독성제 접합체에 의한 EGfr 치료에 내성을 나타내는 종양의 치료 방법
AU2011382454B2 (en) 2011-11-30 2017-02-23 Abbvie Biotechnology Ltd Vectors and host cells comprising a modified SV40 promoter for protein expression
WO2013088363A1 (en) * 2011-12-13 2013-06-20 Nordic Nanovector As Chimeric therapeutic anti - cd37 antibodie hh1
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
KR102203056B1 (ko) 2011-12-22 2021-01-14 얀센 바이오테크 인코포레이티드 인간 배아 줄기 세포의 단일 인슐린 호르몬 양성 세포로의 분화
EA036740B1 (ru) 2011-12-28 2020-12-15 Эмджен Инк. Способ увеличения высоты альвеолярного отростка посредством применения антител к склеростину
CN104159920A (zh) 2011-12-30 2014-11-19 艾伯维公司 针对il-13和/或il-17的双重可变结构域免疫球蛋白
NZ629697A (en) 2012-03-15 2017-01-27 Janssen Biotech Inc Human anti-cd27 antibodies, methods and uses
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
EP2834259A4 (en) 2012-04-02 2016-08-24 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES
BR112014025693B1 (pt) 2012-04-17 2021-12-07 F. Hoffmann-La Roche Ag Método de produção recombinante de um polipeptídeo em uma célula bacteriana
KR102667288B1 (ko) 2012-06-08 2024-05-17 얀센 바이오테크 인코포레이티드 인간 배아 줄기 세포의 췌장 내분비 세포로의 분화
WO2014006100A1 (en) 2012-07-05 2014-01-09 Ucb Pharma S.A. Treatment for bone diseases
WO2014042251A1 (ja) 2012-09-13 2014-03-20 中外製薬株式会社 遺伝子ノックイン非ヒト動物
US9487590B2 (en) 2012-09-25 2016-11-08 Cytomx Therapeutics, Inc. Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
MY171664A (en) 2012-11-01 2019-10-22 Abbvie Inc Anti-dll4/vegf dual variable domain immunoglobulins and uses thereof
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
RU2768963C2 (ru) 2012-12-31 2022-03-25 Янссен Байотек, Инк. Культивация эмбриональных стволовых клеток человека в воздушно-жидкостной зоне взаимодействия с целью их дифференцировки в панкреатические эндокринные клетки
US10370644B2 (en) 2012-12-31 2019-08-06 Janssen Biotech, Inc. Method for making human pluripotent suspension cultures and cells derived therefrom
WO2014105546A1 (en) 2012-12-31 2014-07-03 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into pancreatic endocrine cells using hb9 regulators
WO2014106141A1 (en) 2012-12-31 2014-07-03 Janssen Biotech, Inc. Suspension and clustering of human pluripotent cells for differentiation into pancreatic endocrine cells
JP2016522793A (ja) 2013-03-15 2016-08-04 アッヴィ・インコーポレイテッド ＩＬ−１βおよび／またはＩＬ−１７に対して指向された二重特異的結合タンパク質
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
FI3677591T3 (fi) 2013-04-29 2023-04-03 Teva Pharmaceuticals Australia Pty Ltd Anti-cd38-vasta-aineet ja fuusiot heikennetylle interferonille alfa-2b
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
WO2014200018A1 (ja) 2013-06-11 2014-12-18 独立行政法人 国立精神・神経医療研究センター 再発寛解型多発性硬化症（ｒｒｍｓ）患者の治療予後予測方法、及び新規治療適応判断方法
KR102248581B1 (ko) 2013-07-04 2021-05-06 에프. 호프만-라 로슈 아게 혈청 샘플 중 항-약물 항체를 검출하기 위한 간섭-억제된 면역분석
SG10201803449VA (en) 2013-09-27 2018-05-30 Chugai Pharmaceutical Co Ltd Method for producing polypeptide heteromultimer
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
DE202014010499U1 (de) 2013-12-17 2015-10-20 Kymab Limited Targeting von humaner PCSK9 zur Cholesterinbehandlung
US9758578B2 (en) 2013-12-26 2017-09-12 Mitsubishi Tanabe Pharma Corporation Human anti-IL-33 neutralizing monoclonal antibody
EP4671270A3 (en) 2013-12-27 2026-03-18 Chugai Seiyaku Kabushiki Kaisha Method for purifying antibody having low isoelectric point
EP2898896A1 (en) 2014-01-22 2015-07-29 Université Pierre et Marie Curie (Paris 6) Agents for use in the treatment of retinal inflammation
WO2015116852A1 (en) 2014-01-29 2015-08-06 Regeneron Pharmaceuticals, Inc. Methods for treating rheumatoid arthritis by administering an il-6r antibody
TWI731535B (zh) 2014-03-21 2021-06-21 美商艾伯維有限公司 抗-egfr抗體及抗體藥物結合物
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
EP3954759A1 (en) 2014-05-16 2022-02-16 Janssen Biotech, Inc. Use of small molecules to enhance mafa expression in pancreatic endocrine cells
EP3185004A4 (en) 2014-08-20 2018-05-30 Chugai Seiyaku Kabushiki Kaisha Method for measuring viscosity of protein solution
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
CA2963712A1 (en) 2014-10-21 2016-04-28 Ablynx Nv Treatment of il-6r related diseases
EA037749B1 (ru) 2014-10-29 2021-05-18 Тева Фармасьютикалз Острэйлиа Пти Лтд ВАРИАНТЫ ИНТЕРФЕРОНА 2b
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
MA41142A (fr) 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
US11384350B2 (en) 2014-12-15 2022-07-12 The Regents Of The University Of California Cytotoxic molecules responsive to intracellular ligands for selective T cell mediated killing
WO2016100232A1 (en) 2014-12-15 2016-06-23 The Regents Of The University Of California Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
TWI656133B (zh) 2014-12-19 2019-04-11 日商中外製藥股份有限公司 抗肌抑素之抗體、含變異Ｆｃ區域之多胜肽及使用方法
KR101838645B1 (ko) 2014-12-19 2018-03-14 추가이 세이야쿠 가부시키가이샤 항-c5 항체 및 그의 사용 방법
WO2016125495A1 (en) 2015-02-05 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
EP3263132B1 (en) 2015-02-27 2023-12-06 Chugai Seiyaku Kabushiki Kaisha Composition for treating il-6-related diseases
AR104050A1 (es) 2015-03-26 2017-06-21 Chugai Pharmaceutical Co Ltd Proceso de producción con iones de cobre controlados
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
US10697883B2 (en) 2015-05-19 2020-06-30 National Center Of Neurology And Psychiatry Method for determining application of therapy to multiple sclerosis (MS) patient
EP3305325B1 (en) 2015-06-04 2025-07-30 National Center of Neurology and Psychiatry Mental illness therapeutic agent having il-6 inhibitor as active ingredient
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
JP2018523684A (ja) 2015-08-18 2018-08-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体
EP3371224A1 (en) 2015-11-03 2018-09-12 Sanofi Biotechnology Compositions comprising il6r antibodies for the treatment of uveitis and macular edema and methods of using same
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
CA3004288C (en) 2015-12-28 2025-05-27 Chugai Seiyaku Kabushiki Kaisha METHOD FOR PROMOTING THE CLEARANCE EFFICIENCY OF A POLYPEPTIDE CONTAINING THE FC REGION
WO2017147169A1 (en) 2016-02-22 2017-08-31 Ohio State Innovation Foundation Chemoprevention using controlled-release formulations of anti-interleukin 6 agents, synthetic vitamin a analogues or metabolites, and estradiol metabolites
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
TW202214700A (zh) 2016-03-14 2022-04-16 日商中外製藥股份有限公司 用於癌之治療的細胞傷害誘導治療劑
CA3020905A1 (en) 2016-04-14 2017-10-19 Janssen Biotech, Inc. Differentiation of pluripotent stem cells to intestinal midgut endoderm cells
AU2017255077B2 (en) 2016-04-28 2024-05-16 Chugai Seiyaku Kabushiki Kaisha Antibody-containing preparation
CN109689099B (zh) 2016-08-05 2023-02-28 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
KR20190057308A (ko) 2016-09-02 2019-05-28 더 리전츠 오브 더 유니버시티 오브 캘리포니아 인터류킨-6 수용체 알파-결합 단일 사슬 가변 단편을 포함하는 방법 및 조성물
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
KR102546471B1 (ko) 2016-09-27 2023-06-21 프레제니우스 카비 도이치란트 게엠베하 액상의 약학 조성물
KR102051177B1 (ko) * 2016-10-19 2019-12-17 주식회사 엘지화학 전압 분배를 이용한 스위치 진단 장치 및 방법
EP3964197A1 (en) 2016-10-31 2022-03-09 Fresenius Kabi Deutschland GmbH Liquid pharmaceutical composition
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
EP3596175A4 (en) 2017-03-17 2021-01-13 The Ohio State Innovation Foundation NANOPARTICLES FOR THE ADMINISTRATION OF CHEMOPREVENTIVE AGENTS
EP3620531A4 (en) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS
CN107098969B (zh) * 2017-06-28 2018-10-12 武汉波睿达生物科技有限公司 一种治疗hiv感染的嵌合抗原受体的重组基因构建及其应用
CN115920032A (zh) 2017-08-31 2023-04-07 田边三菱制药株式会社 含有il-33拮抗剂的子宫内膜异位症治疗剂
CN111051343B (zh) 2017-09-13 2022-11-22 江苏恒瑞医药股份有限公司 Il-6r抗体、其抗原结合片段及医药用途
US11692037B2 (en) 2017-10-20 2023-07-04 Hyogo College Of Medicine Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
BR112020008393A2 (pt) 2017-11-01 2020-11-03 Chugai Seiyaku Kabushiki Kaisha variante e isoforma de anticorpos com atividade biológica reduzida
TWI822728B (zh) 2018-01-31 2023-11-21 加藤元一 含有il-6抑制劑的哮喘治療劑
IL277375B2 (en) 2018-03-15 2025-08-01 Chugai Pharmaceutical Co Ltd Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
CN119241705A (zh) 2018-03-30 2025-01-03 安姆根有限公司 C末端抗体变体
CN112512480B (zh) 2018-05-21 2024-10-01 中外制药株式会社 被封入玻璃容器的冷冻干燥制剂
EP3805112A4 (en) 2018-05-28 2022-03-09 Chugai Seiyaku Kabushiki Kaisha FILLING NOZZLE
CN112955222A (zh) 2018-08-29 2021-06-11 里珍纳龙药品有限公司 用于治疗患有类风湿性关节炎的个体的方法和组合物
US20220096548A1 (en) * 2019-01-07 2022-03-31 Hunan Siweikang Therapeutics Co. Ltd. Modified immune cells co-expressing chimeric antigen receptor and il-6 antagonist for reducing toxicity and uses thereof in adoptive cell therapy
TW202521583A (zh) 2019-01-31 2025-06-01 法商賽諾菲生物技術公司 用於治療幼年原發性關節炎之組成物及方法
MX2021011464A (es) 2019-03-29 2021-10-22 Chugai Pharmaceutical Co Ltd Inhibidor que contiene anticuerpo del receptor anti-interleucina 6 (il-6) para inhibir el deterioro de la funcion de la barrera hemato-encefalica (bbb).
WO2020201362A2 (en) 2019-04-02 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
JP7583411B2 (ja) 2019-04-10 2024-11-14 中外製薬株式会社 Ｆｃ領域改変抗体の精製方法
MX2021012163A (es) 2019-04-17 2022-01-31 Univ Hiroshima Agente terapeutico para cancer urologico que se caracteriza por ser administrado con un inhibidor de il-6 y un inhibidor de ccr2 en combinacion.
MA55760A (fr) 2019-04-24 2022-03-02 Regeneron Pharma Procédés de diagnostic et de traitement de la polyarthrite rhumatoïde
WO2020243479A1 (en) 2019-05-31 2020-12-03 The Johns Hopkins University Bispecific binding agents
JP2022534794A (ja) 2019-06-04 2022-08-03 サノフィ・バイオテクノロジー 関節リウマチを有する対象における疼痛を治療するための組成物および方法
US20200405883A1 (en) 2019-06-20 2020-12-31 Baxalta Incorporated Method of treatment with viral-based gene therapy
CN110483640B (zh) * 2019-07-16 2020-05-01 北京汇智和源生物技术有限公司 白介素-6r的人源化单克隆抗体、其编码基因及应用
BR112022017574A2 (pt) 2020-03-03 2022-11-16 Twentyeight Seven Inc Compostos que têm como alvo proteínas de ligação ao rna ou proteínas modificadoras de rna
US20230125415A1 (en) 2020-03-23 2023-04-27 Genentech, Inc. Biomarkers for predicting response to il-6 antagonist in covid-19 pneumonia
US20230174656A1 (en) 2020-03-23 2023-06-08 Genentech, Inc. Tocilizumab and remdesivir combination therapy for covid-19 pneumonia
JP2023518815A (ja) 2020-03-23 2023-05-08 ジェネンテック， インコーポレイテッド Ｉｌ６アンタゴニストによるｃｏｖｉｄ－１９肺炎を含む肺炎の治療方法
WO2021211006A1 (en) 2020-04-13 2021-10-21 Federal State Budgetary Institution Center Of Biomedical Technologies Of Federal Medical And Biological Agency Inhaled hexapeptide for treating interleukin-6 related respiratory diseases
WO2021228917A1 (en) 2020-05-15 2021-11-18 F. Hoffmann-La Roche Ag Prevention of visible particle formation in parenteral protein solutions
CN115667297B (zh) * 2020-05-18 2026-02-03 博奥信生物技术（南京）有限公司 结合il6r的抗体及其用途
CN115697404A (zh) 2020-05-29 2023-02-03 中外制药株式会社 含有抗体的制剂
WO2022005321A1 (en) 2020-06-29 2022-01-06 Federal State Budgetary Institution Scientific center of biomedical technologies of Federal Medical and Biological Agency Inhaled tocilizumab for treating interleukin-6 related respiratory diseases
KR20220028972A (ko) 2020-08-31 2022-03-08 (주)셀트리온 안정한 약제학적 제제
CN116685351A (zh) 2020-09-17 2023-09-01 基因泰克公司 Empacta的结果：一项用于评估托珠单抗在患有covid-19肺炎的住院患者中的功效和安全性的随机、双盲、安慰剂对照、多中心研究
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
WO2022165419A1 (en) 2021-02-01 2022-08-04 Kyverna Therapeutics, Inc. Methods for increasing t-cell function
EP4306127A4 (en) 2021-03-12 2025-04-09 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for the treatment or prevention of myasthenia gravis
MX2023014658A (es) 2021-06-11 2024-01-12 Genentech Inc Metodo para tratar la enfermedad pulmonar obstructiva cronica con un antagonista de st2.
WO2023058723A1 (ja) 2021-10-08 2023-04-13 中外製薬株式会社 プレフィルドシリンジ製剤の調製方法
WO2023210670A1 (ja) 2022-04-26 2023-11-02 中外製薬株式会社 医薬製剤含有フィルター内蔵シリンジ
WO2024107752A2 (en) 2022-11-15 2024-05-23 Onestone Therapeutics Llc Compositions and methods for immunomodulatory bifunctional fusion molecules
JPWO2024204671A1 (enExample) 2023-03-31 2024-10-03
EP4696321A1 (en) 2023-04-14 2026-02-18 Chugai Seiyaku Kabushiki Kaisha Method for stabilizing protein-containing pharmaceutical preparation
WO2025198912A1 (en) 2024-03-21 2025-09-25 Hoffmann-La Roche Inc. Methods of treating myasthenia gravis
HUP2400216A1 (hu) 2024-04-17 2025-10-28 Richter Gedeon Nyrt N-terminális glutamint tartalmazó immunglobulinok tisztítására szolgáló eljárások

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6147500A (ja) * 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
JPS62296890A (ja) * 1986-03-27 1987-12-24 メディカル　リサーチ　カウンスル 組換えｄｎａ生産物及び製造法
EP0409607A2 (en) * 1989-07-20 1991-01-23 Tadamitsu Kishimoto Antibody to human interleukin-6 receptor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4304583A (en) * 1980-06-02 1981-12-08 Corning Glass Works Process for drying optical waveguide preforms
GB8422238D0 (en) * 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5082782A (en) 1988-12-27 1992-01-21 Worcester Polytechnic Institute Production of horseshoe crab amebocytes in vitro
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5216128A (en) * 1989-06-01 1993-06-01 Yeda Research And Development Co., Ltd. IFN-β2/IL-6 receptor its preparation and pharmaceutical compositions containing it
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
FR2943539B1 (fr) 2009-03-31 2011-07-22 Ethypharm Sa Composition pharmaceutique comprenant un macrolide immunosuppresseur de la famille des limus.
EP2409607A1 (de) 2010-07-20 2012-01-25 Josef Kurz Schuhlöffel

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6147500A (ja) * 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
JPS62296890A (ja) * 1986-03-27 1987-12-24 メディカル　リサーチ　カウンスル 組換えｄｎａ生産物及び製造法
EP0409607A2 (en) * 1989-07-20 1991-01-23 Tadamitsu Kishimoto Antibody to human interleukin-6 receptor

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101510831B1 (ko) * 2012-05-11 2015-04-10 가톨릭대학교 산학협력단 항 ｉｌ-６ｒ 및 ｔｎｆｒ２을 포함하는 이중특이적 단백질을 발현하는 미니서클 벡터를 포함하는 줄기세포 치료제
KR101510302B1 (ko) * 2012-05-11 2015-04-10 가톨릭대학교 산학협력단 Ｉｌ-６ 수용체를 표적으로 하는 항체가 생성되도록 미니서클 벡터를 통해 형질전환된 줄기세포 치료제
KR101510830B1 (ko) 2012-05-11 2015-04-10 가톨릭대학교 산학협력단 생리활성 단백질을 발현하는 미니서클을 이용하여 형질전환된 줄기세포를 통한 치료법

Also Published As

Publication number Publication date
JP2008073049A (ja) 2008-04-03
HU9303002D0 (en) 1994-01-28
EP0628639B1 (en) 1999-06-23
HU218140B (hu) 2000-06-28
JP3913965B2 (ja) 2007-05-09
DE69229482T2 (de) 1999-11-18
JP3370324B2 (ja) 2003-01-27
AU668349B2 (en) 1996-05-02
AU1674092A (en) 1992-12-21
ATE181575T1 (de) 1999-07-15
JP2007082560A (ja) 2007-04-05
JP2001083151A (ja) 2001-03-30
WO1992019759A1 (fr) 1992-11-12
DE69229482D1 (de) 1999-07-29
JP3176598B2 (ja) 2001-06-18
EP0628639A1 (en) 1994-12-14
DE122009000019I1 (de) 2009-07-16
HUT70258A (en) 1995-09-28
GR3031174T3 (en) 1999-12-31
US5817790A (en) 1998-10-06
JP2004045433A (ja) 2004-02-12
AU692100B2 (en) 1998-05-28
JP2000116391A (ja) 2000-04-25
RU2139351C1 (ru) 1999-10-10
US7479543B2 (en) 2009-01-20
TW205553B (enExample) 1993-05-11
NL300383I1 (nl) 2009-06-02
LU91556I2 (fr) 2009-06-24
ES2134212T3 (es) 1999-10-01
US5795965A (en) 1998-08-18
EP0628639A4 (en) 1994-12-28
JP3616087B2 (ja) 2005-02-02
AU5621396A (en) 1996-10-24
DK0628639T3 (da) 2000-01-24
US20050142635A1 (en) 2005-06-30
NL300383I2 (nl) 2010-02-01

Similar Documents

Publication Publication Date Title
KR100249937B1 (ko) 인간 인터루킨-6 수용체에 대한 재구성 인간 항체
JP7410143B2 (ja) 二重特異性抗体及びその用途
JP3854306B2 (ja) ヒト化及びキメラモノクローナル抗体
US5856135A (en) Reshaped human antibody to human interleukin-6
JPWO1992019759A1 (ja) ヒトインターロイキン−６受容体に対する再構成ヒト抗体
EP0737250A1 (en) Humanized antibodies and uses thereof
SK16762000A3 (sk) Protilátky proti cd23, farmaceutický prostriedok s ich obsahom, sekvencie dna kódujúce reťazec protilátok a použitie protilátok
CA2834983A1 (en) Anti-nerve growth factor antibodies and methods of preparing and using the same
JP3614183B2 (ja) ヒトインターロイキン−６に対する再構成ヒト抗体
JPH05227970A (ja) ヒトインターロイキン−６受容体に対する再構成ヒト抗体
CN111303283A (zh) 抗il-17a抗体及其应用
US20260062479A1 (en) Anti-tirc7 antigen binding proteins
GB2528811A (en) Anti-nerve growth factor antibodies and methods of preparing and using the same
HK40057229B (en) Anti-il-17a antibody and use thereof
HK40052031A (en) Bispecific antibody and use thereof
JPH05236966A (ja) ヒトインターロイキン−６レセプターに対するマウスモノクローナル抗体の可変領域をコードするｄｎａ

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 19931025

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19970423

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19990121

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19990625

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 19990929

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 19991229

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 19991230

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20021108

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20031119

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20041223

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20051219

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20061110

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20071224

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20081224

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20091224

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20101208

Start annual number: 12

End annual number: 12

FPAY Annual fee payment

Payment date: 20111202

Year of fee payment: 13

PR1001 Payment of annual fee

Payment date: 20111202

Start annual number: 13

End annual number: 13

EXPY Expiration of term
PC1801 Expiration of term

Termination date: 20130109

Termination category: Expiration of duration